{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T06:19:22Z","timestamp":1778739562155,"version":"3.51.4"},"reference-count":34,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T00:00:00Z","timestamp":1589414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Addict"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>There have been few reports of buprenorphine treatment of opioid use disorder in private psychiatric practice. This report describes such a patient population and the outcomes obtained.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Chart reviews were performed on 285 patients seen over a 10\u2010year period in the author\u2019s solo private psychiatric practice. Quantitative and qualitative data were reviewed and analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Comorbidity of psychiatric disorders was high (75%), while comorbidity of substance use disorders was low (5%, alcohol only). Fourteen percent of patients completed treatment (tapered off of buprenorphine and remained opioid\u2010free for up to 7 years). Forty\u2010eight percent of the sample had good outcomes (remaining on buprenorphine and abstinent of other opioids), 28% had poor outcomes, and 10% dropped out of prolonged successful treatment with unknown final outcomes. The group achieved a relatively high rate of smoking cessation during the study (22%). There were high rates of language disorder (21.6%) and autism spectrum disorder (8.6%) in children of mothers in the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion and Conclusion<\/jats:title><jats:p>Outcomes were excellent compared with those reported in other treatment settings. Rates of smoking cessation were also notable. The treatment of comorbid psychiatric conditions, the setting to develop a strong physician\u2010patient relationship, patients choosing whether to taper off of buprenorphine, and the slow rate of taper all likely contributed to successful outcomes. Further investigation is needed regarding possible increased rates of developmental disorders in children of mothers treated with buprenorphine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Scientific Significance<\/jats:title><jats:p>Private psychiatric practice is a highly successful domain for the treatment of opioid use disorder. (Am J Addict 2020;29:508\u2013514)<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajad.13060","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T06:21:43Z","timestamp":1589523703000},"page":"508-514","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ten Years of Experience With Buprenorphine in a Private Psychiatric Outpatient Practice"],"prefix":"10.1111","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3959-497X","authenticated-orcid":false,"given":"Robert","family":"Feder","sequence":"first","affiliation":[{"name":"Private Practice Manchester New Hampshire"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,5,14]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2016.12.010"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13238"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12896"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-017-3993-2"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.541"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1089\/pop.2018.0163"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12553"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.12.001"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2014.12.011"},{"key":"e_1_2_7_11_1","unstructured":"Centers for Disease Control and Prevention. Opioid Morphine Equivalent Conversion Factors;2017.https:\/\/www.cms.gov\/Medicare\/Prescription-Drug-Coverage\/PrescriptionDrugCovContra\/Downloads\/Opioid-Morphine-EQ-Conversion-Factors-April-2017.pdf"},{"key":"e_1_2_7_12_1","first-page":"43","article-title":"Comparative analgesic potency of heroin and morphine in postoperative patients","volume":"136","author":"Reichle CW","year":"1962","journal-title":"J Pharmacol Exp."},{"key":"e_1_2_7_13_1","unstructured":"Drug Enforcement Administration. 2016 national drug price and purity data.DEA Intelligence Report. July 2018. DEA\u2010DCW\u2010DIR\u2010023\u201018."},{"key":"e_1_2_7_14_1","unstructured":"Drug Enforcement Administration. Conversion factors for controlled substances. Diversion Control Division; 2019."},{"key":"e_1_2_7_15_1","unstructured":"National Institute of Mental Health. Statistics pages; 2018.https:\/\/www.nimh.nih.gov\/health\/statistics\/index.shtml"},{"key":"e_1_2_7_16_1","unstructured":"National Institutes of Health. Publication Number 10\u20105771; 2010.http:\/\/www.drugabuse.gov\/publications\/research-reports\/comorbidity-addiction-other-mental-illnesses\/letter-director"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12448"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000484240"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2017.01.052"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j760"},{"key":"e_1_2_7_21_1","unstructured":"FDA. U.S. Food and Drug Administration Drug Safety Communications: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks; 2017."},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/15504263.2013.867657"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntx189"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntx113"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-017-0072-2"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.07.013"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.05.033"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.05.010"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.5302"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/136828200247133"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.17812"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-018-3721-8"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-0128"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13034-019-0266-3"},{"key":"e_1_2_7_35_1","first-page":"544","article-title":"Effects of opioid use in pregnancy on pediatric development and behavior in children older than age 2","volume":"65","author":"Welton S","year":"2019","journal-title":"Can Fam Physician"}],"container-title":["The American Journal on Addictions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajad.13060","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajad.13060","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajad.13060","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajad.13060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T11:15:45Z","timestamp":1693307745000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajad.13060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,14]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1111\/ajad.13060"],"URL":"https:\/\/doi.org\/10.1111\/ajad.13060","archive":["Portico"],"relation":{},"ISSN":["1055-0496","1521-0391"],"issn-type":[{"value":"1055-0496","type":"print"},{"value":"1521-0391","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,14]]},"assertion":[{"value":"2019-11-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}